Flavopiridol methods and compositions for HIV therapy
AssigneesUniversity of Iowa Research Foundation, The United States of America as represented by the Department of Health and Human Services
InventorsDavid H. Price, Adrian M. Senderowicz
Life of this patent
Estimating the term…
Abstract
Disclosed is the unexpected discovery that flavopiridol binds tightly to the transcription elongation factor, P-TEFb and dramatically inhibits its activity. As P-TEFb is required for HIV propagation and replication, this invention provides new methods, compositions and kits for the effective treatment of HIV infections and AIDS using flavopiridol, both alone and combination with other therapies.
Claims11
A method for inhibiting P-TEFb, comprising contacting P-TEFb with an amount of an flavopiridol compound effective to inhibit said P-TEFb.
A method for inhibiting viral transcription, comprising providing to a system competent to perform viral transcription an amount of a flavopiridol compound effective to inhibit the cyclin-dependent kinase subunit of P-TEFb within said system, thereby inhibiting viral transcription.
A method for inhibiting viral replication or propagation in a mammalian cell, comprising providing a flavopiridol compound to a mammalian cell infected with a virus in an amount effective to inhibit P-TEFb within said cell, thereby inhibiting viral transcription, replication and propagation in said cell.
A method for inhibiting HIV replication or propagation in a patient, comprising providing a flavopiridol compound to a patient infected, or suspected of being infected, with HIV in an amount effective to inhibit P-TEFb within cells of said patient, thereby inhibiting HIV transcription, replication and propagation in said cells of said patient.
Dependencies are inferred from the claim text.